BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Cancer Res
; 75(4): 732-41, 2015 Feb 15.
Article
em En
| MEDLINE
| ID: mdl-25511378
ABSTRACT
Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. We found that multidrug resistance was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b gene, which encodes the drug efflux transporter P-glycoprotein. Inhibition of P-glycoprotein could partly resensitize sarcomatoid tumors to the PARP inhibitor olaparib, docetaxel, and doxorubicin. We propose that multidrug resistance is a multifactorial process and that mouse models are useful to unravel this.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Mamárias Animais
/
Resistência a Múltiplos Medicamentos
/
Subfamília B de Transportador de Cassetes de Ligação de ATP
/
Proteína BRCA2
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Cancer Res
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Holanda